Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A2009 in advanced solid tumors
NCT05394818Phase 1Completed
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Jul 2022
- Primary completion
- Apr 2024
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ruzaltatug rezetecan in solid tumor (advanced stage), sponsored by Suzhou Suncadia Biopharmaceutical. Primary endpoints: Maximum tolerated dose or maximum administered dose, Recommended Phase 2 dose and 1 more. Started Jul 2022; status: completed.
02
Drugs
ruzaltatug rezetecan
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05394818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05394818.